熱門資訊> 正文
AVRO比奥GAAP每股收益为-1.20美元
2024-11-08 13:21
- AVROBIO press release (NASDAQ:TECX): Q3 GAAP EPS of -$1.20.
- Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027
-
More on AVROBIO
- Tectonic Therapeutic: Interesting CV Disease Drug Developer
- Tectonic draws bullish view at Wells Fargo on lead asset
- Historical earnings data for AVROBIO
- Financial information for AVROBIO
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。